First gene therapy to go on sale in 2013

| November 7, 2012
c gene therapy conc
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

The first gene therapy to be approved in a regulated market was announced by the European Commission, which granted its approval to a treatment for the rare inherited disorder lipoprotein lipase deficiency (LPL). This genetic disorder leaves people unable to store fat in adipose and muscle cells. The new drug has been named Glybera by its maker, UniQure. The therapy, which manufacturers say will be available next year, uses a virus to insert a working copy of the gene into muscle.

Related Articles:


View the original article here:

The GLP featured this article to reflect the diversity of news, opinion and analysis. The viewpoint is the author’s own. The GLP’s goal is to stimulate constructive discourse on challenging science issues.

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend